---
layout: post
title: "Model Informed Drug Development Approaches for Immunogenicity Assessments; Public Workshop"
date: 2026-02-05 19:09:22 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2021-08487
original_published: 2021-04-23 00:00:00 +0000
significance: 8.00
---

# Model Informed Drug Development Approaches for Immunogenicity Assessments; Public Workshop

**Published:** February 05, 2026 19:09 UTC
**Source:** Federal Register
**Original Published:** April 23, 2021 00:00 UTC
**Document Number:** 2021-08487

## Summary

The Food and Drug Administration (FDA) Center for Biologics Evaluation and Research, in collaboration with the Center for Drug Evaluation and Research, is announcing the following public workshop entitled "Model Informed Drug Development Approaches for Immunogenicity Assessments." The purpose of this public workshop is to discuss the best practices and future directions of quantitative methods for predicting immunogenicity of biological products. This public workshop is also being conducted to satisfy one of FDA's performance goals included in the sixth reauthorization of the Prescription Drug User Fee Amendments (PDUFA VI), part of the FDA Reauthorization Act of 2017 (FDARA), to hold a series of workshops related to model-informed drug development (MIDD).

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2021/04/23/2021-08487/model-informed-drug-development-approaches-for-immunogenicity-assessments-public-workshop)
- API: https://www.federalregister.gov/api/v1/documents/2021-08487

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
